{"task_id": "5e97e110bafee6f9", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 236/464)", "text": "SYNDROME) (CONT\u2019D)\nHereditary Cancer Syndromes\n225\n\n--- Page 247 ---\nFAMILIAL ADENOMATOUS POLYPOSIS (FAP)\nGENETICS\nautosomal dominant, 5q21 q22\nPATHOPHYSIOLOGY\nadenomatosis polyposis coli\n(APC) gene, a tumor suppressor gene that normally\nprevents accumulation of b catenin by facilitating its\nphosphorylation and resultant degradation. One\nthird of patients have no family history (new germline\nAPC mutations or due to MYH gene mutations)\nCANCER TYPES\ncolorectal (risk approaches 100%\nby age 45), duodenal ampullary, gastric, follicular or\npapillary thyroid, hepatoblastoma, medulloblastoma\n(Turcot\u2019s syndrome)\nFEATURES\ncolon polyps (more than 100), duodenal\nadenomatous polyps, extraintestinal manifestations\n(Gardner\u2019s syndrome) such as desmoid tumors,\nsebaceous or epidermoid cysts, lipomas, osteomas,\nsupernumerary teeth, gastric polyps ,and juvenile\nnasopharyngeal angiofibromas\nSURVEILLANCE (all at risk family member)\nsigmoi\ndoscopy or colonoscopy annually starting age 10 12.\nUpper endoscopy. Annual thyroid palpation\nPROPHYLAXIS\ntotal proctocolectomy at time of\ndiagnosis in patients with multiple large (>1 cm)\nadenomas or adenomas with villous histology and/\nor high grade dysplasia\nAntineoplastic Agents\nChemotherapeutic\nagents\nActivitya\nMyelo.\nsupp.\nEmetogenic\nrisk\nAlopecia\nOther major toxicities\nb\nDose\nmodification\nc\nAlkylating agents\nCyclophosphamide (Cytoxan,\nIV/PO)\nBR, GYN, NHL, BMT\n+++\n++(+)\n+++\nHemorrhagic cystitis, muco, sterility\nRenal, hepatic\nIfosfamide (IV)\nT, SA, NHL\n+++\n++\n+++\nHemorrhagic cystitis, neuro\nRenal\nMelphalan (PO)\nMM, BMT\n++\n+\n+\nMucositis, sterility\nRenal\nChlorambucil (PO)\nNHL, CLL\n++\n+\nMucositis, sterility\nBulsulfan (PO)\nBMT\n+++\n+\n++\nPulmonary\nRenal\nCarmustine (BCNU, IV)\nCNS, NHL\n+++\n+++\n+\nPulmonary,renal, muco, diarrhea, LFT\nRenal\nLomustine (CCNU, PO)\nCNS, NHL\n+++\n++\n++\nPulmonary, renal, muco, diarrhea, LFT\nRenal\nDacarbazine (DTIC, IV)\nNHL, melanoma, SA\n++\n+++\n+\nFlu like symptoms, LFT, photo\nRenal, hepatic\nTemozolomide (PO)\nCNS, melanoma\n++\n++\n+\nPhotosensitivity\nRenal, hepatic\nStreptozocin (IV)\nCarcinoid, islet cell\n+\n+++\n+\nRenal, diarrhea, LFT, hypoglycemia\nRenal\nAntimetabolites\nMethotrexate (IV/PO)\nALL, chorio,\nleptomeningeal\n++\n+\n+\nMuco, diarrhea, LFT, renal, pulm, neuro\nRenal, hepatic\nPemetrexed (IV)\nLU, mesothelioma, BR\n++\n+\n+\nMucositis, diarrhea, hand foot\nRenal\nRaltitrexed (IV)\nGI, BR\n++\n+\n+\nMucositis, diarrhea, LFT, fatigue\nRenal\n5 Fluorouracil (IV)\nGI, BR\n+\n+\n++\nMuco, diarrhea, hand foot, cerebellar\nHepatic\nCapecitabine (xeloda, PO)\nGI, BR\n++\n+\n+\nMuco, diarrhea, LFT, hand foot, neuro\nRenal\nCytosine arabinoside (Ara C, IV)\nALL, NHL,\nleptomeningeal\n+++\n+(+)\n++\nMucositis, diarrhea, cerebellar\nRenal, hepatic,\nneuro\nGemcitabine (IV)\nGI, LU, BR, NPC,\nbladder\n++\n+\n++\nDiarrhea, LFT, flu like, rash\nRenal, hepatic\nHydroxyurea (PO, IV)\nAML, CML\n++\n+\n+\nMucositis, rash\nRenal\n6 Thioguanine (6 TG, IV)\nAML\n++\n+\n+\nMucositis, diarrhea, LFT\nHepatic\n6 Mercaptopurine (6 MG, IV)\nALL\n++\n+\n+\nMucositis, diarrhea, LFT\nRenal, hepatic\nFludarabine (IV, PO)\nNHL, CLL\n++\n+\n+\nNeuro, AIHA, LFT\nRenal\n2 Chlorodeoxyadenosine\n(cladribine, IV)\nNHL, hairy cell\nleukemia\n++\n+\n+\nConstipation, fever\nTopoisomerase inhibitors\nDoxorubicin\n(hydroxydaunomycin, IV)\nBR, SA\n+++\n++\n+++\nCardiac\nHepatic\nDoxorubicin (liposomal, IV)\nKS, OV\n++\n+\n+++\nCardiac, infusion, skin\nHepatic\nDaunorubicin (IV)\nAML, neuroblastoma\n+++\n++\n+++\nCardiac\nHepatic\nIdarubicin (PO)\nAML\n+++\n++\n+++\nCardiac (less)\nHepatic, renal\nEpirubicin (IV)\nBR\n+++\n++\n+++\nCardiac\nHepatic\nMitoxantrone (IV)\nAML, BR, prostate\n++\n+\n+\nCardiac, LFT\nHepatic\nEtoposide (IV/PO)\nLU, T, NHL\n++\n+\n+++\nNeuro, LFT\nHepatic, renal\nTopotecan (IV)\nOV, LU\n+++\n+\n+++\nDiarrhea, constipation, fever\nRenal\nIrinotecan (IV)\nGI, LU, GYN\n++\n+\n+++\nDiarrhea, constipation, fever\nHepatic\nPlatinating agents\nCisplatin (IV)\nBladder, LU, T, OV\n++\n+++\n+\nRenal, neuro, ototoxicity\nRenal, neuro\nCarboplatin (IV)\nBladder, LU, T, OV\n++\n++\n+\nRenal, neuro, ototoxicity (less)\nRenal\nOxaliplatin (IV)\nGI\n+\n++\n+\nNeuro, diarrhea\nNeuro, renal\nAntimicrotubular agents\nVincristine (oncovin, IV)\nNHL\n+\n++\nNeuro, constipation\nHepatic, neuro\nVinblastine (IV)\nT, NHL\n++\n+\n++\nCramps, neuro, constipation\nHepatic, neuro\nVinorelbine (navelbine, IV)\nLU, BR\n++\n+\n+++\nNeuro, constipation, diarrhea\nHepatic\nDocetaxel (taxotere, IV)\nBR, LU, prostate, OV\n++\n+\n+++\nInfusion, neuro, nails, myalgia,\narthralgia, edema\nHepatic\nPaclitaxel (taxol, IV)\nBR, LU, prostate, OV\n++\n+\n+++\nNeuro, nails, myalgia, arthralgia\nHepatic, neuro\nFAMILIAL ADENOMATOUS POLYPOSIS (FAP)\n(CONT\u2019D)\n226\nAntineoplastic Agents", "text_length": 4532, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 236/464)", "type": "chunk", "chunk_index": 235, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.571565", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.572296", "status": "complete", "chunks_added": 3}